MX2009010280A - Composicion y microesfera para liberacion controlada de exendina, y metodo para preparar las mismas. - Google Patents
Composicion y microesfera para liberacion controlada de exendina, y metodo para preparar las mismas.Info
- Publication number
- MX2009010280A MX2009010280A MX2009010280A MX2009010280A MX2009010280A MX 2009010280 A MX2009010280 A MX 2009010280A MX 2009010280 A MX2009010280 A MX 2009010280A MX 2009010280 A MX2009010280 A MX 2009010280A MX 2009010280 A MX2009010280 A MX 2009010280A
- Authority
- MX
- Mexico
- Prior art keywords
- controlled
- exendin
- release
- active ingredient
- preparing
- Prior art date
Links
- 239000004005 microsphere Substances 0.000 title abstract 7
- 238000013270 controlled release Methods 0.000 title abstract 6
- 239000000203 mixture Substances 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 3
- 239000004480 active ingredient Substances 0.000 abstract 5
- 229920002988 biodegradable polymer Polymers 0.000 abstract 3
- 239000004621 biodegradable polymer Substances 0.000 abstract 3
- 239000011248 coating agent Substances 0.000 abstract 3
- 238000000576 coating method Methods 0.000 abstract 3
- 239000011247 coating layer Substances 0.000 abstract 2
- 239000002904 solvent Substances 0.000 abstract 2
- 239000000463 material Substances 0.000 abstract 1
- 238000013268 sustained release Methods 0.000 abstract 1
- 239000012730 sustained-release form Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5015—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Vascular Medicine (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Manufacturing Of Micro-Capsules (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Se proporcionan una composición de liberación controlada y microesferas de liberación controlada que contienen una exendina como un ingrediente activo, y un método para preparar las mismas. De manera más específica, se proporcionan una composición de liberación controlada que contiene una exendina como un ingrediente activo, un polímero biodegradable con una viscosidad específica, y materiales de revestimiento, que tiene alta biodisponibilidad y que muestra liberación sostenida del ingrediente activo en una concentración efectiva durante un cierto periodo sin una dehiscencia inicial excesiva del ingrediente activo; microesferas de liberación controlada que contienen un núcleo que incluye una exendina como un ingrediente activo y una polímero biodegradable, y una capa de revestimiento que reviste el núcleo; y un método para preparar las microesferas de liberación controlada que incluye los pasos de mezclar una exendina, un polímero biodegradable, y un solvente, remover el solvente de la mezcla para preparar microesferas endurecidas, y revestir las microesferas endurecidas para formar una capa de revestimiento en la superficie de cada microesfera.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020070029586A KR100805208B1 (ko) | 2007-03-27 | 2007-03-27 | 엑센딘 함유 서방성 제제 조성물, 엑센딘 함유 서방성미립구 및 이의 제조 방법 |
| PCT/KR2008/000397 WO2008117927A1 (en) | 2007-03-27 | 2008-01-22 | Composition and microsphere for controlled-release of exendin, and method of preparing the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2009010280A true MX2009010280A (es) | 2009-10-12 |
Family
ID=39382592
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2009010280A MX2009010280A (es) | 2007-03-27 | 2008-01-22 | Composicion y microesfera para liberacion controlada de exendina, y metodo para preparar las mismas. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9155702B2 (es) |
| EP (1) | EP2134329B1 (es) |
| JP (1) | JP5135428B2 (es) |
| KR (1) | KR100805208B1 (es) |
| CN (1) | CN101646424B (es) |
| AU (1) | AU2008230297B2 (es) |
| BR (1) | BRPI0809326B8 (es) |
| CA (1) | CA2682499C (es) |
| ES (1) | ES2528282T3 (es) |
| IL (1) | IL201024A (es) |
| MX (1) | MX2009010280A (es) |
| MY (1) | MY150087A (es) |
| PL (1) | PL2134329T3 (es) |
| RU (1) | RU2463040C2 (es) |
| WO (1) | WO2008117927A1 (es) |
| ZA (1) | ZA200906381B (es) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2009011275A (es) | 2007-04-19 | 2009-11-02 | Dong A Pharm Co Ltd | Una composicion de microesferas biodegradables adecuadas para la liberacion controlada de peptido de control de la glucosa y formulacion de la misma. |
| US9292307B2 (en) | 2008-07-30 | 2016-03-22 | Kyocera Corporation | User interface generation apparatus |
| US20100183876A1 (en) * | 2008-12-23 | 2010-07-22 | Hell Andre | Process for the Preparation of a Peptide Powder Form |
| EP2538929A4 (en) | 2010-02-25 | 2014-07-09 | Univ Johns Hopkins | DELAYED RELEASE OF THERAPIES IN A PART OF THE EYE |
| CN102370611B (zh) * | 2010-08-17 | 2013-09-18 | 东莞太力生物工程有限公司 | 一种包含exendin-4的温度敏感型水凝胶及其注射剂 |
| EP2665470A1 (en) * | 2011-01-19 | 2013-11-27 | Novo Nordisk A/S | Glp-1 particles and compositions |
| WO2012109363A2 (en) | 2011-02-08 | 2012-08-16 | The Johns Hopkins University | Mucus penetrating gene carriers |
| ES2909777T3 (es) * | 2011-11-18 | 2022-05-10 | Regeneron Pharma | Formulación de liberación prolongada que comprende micropartículas para su uso en el humor vítreo del ojo para tratar trastornos oculares vasculares |
| CN102688198B (zh) * | 2012-06-19 | 2015-04-15 | 广州帝奇医药技术有限公司 | 多肽药物缓释微球制剂及其制备方法 |
| WO2014124006A1 (en) * | 2013-02-05 | 2014-08-14 | The Johns Hopkins University | Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof |
| CN104107165B (zh) * | 2013-04-17 | 2018-11-30 | 长春百益制药有限责任公司 | 一种艾塞那肽微球制剂、其制备方法及其应用 |
| CN104840415B (zh) | 2014-02-19 | 2019-03-15 | 香港浸会大学 | 含有降血糖活性成分的长效控释脂质体凝胶组合物及其制备方法 |
| JP2017511371A (ja) * | 2014-04-16 | 2017-04-20 | シャンドン ルイ ファーマシューティカル カンパニー リミテッド | エクセナチド含有組成物及びその製造方法 |
| US10335500B2 (en) | 2014-05-12 | 2019-07-02 | The Johns Hopkins University | Highly stable biodegradable gene vector platforms for overcoming biological barriers |
| US9480640B2 (en) * | 2014-09-24 | 2016-11-01 | Hongkai Zhang | Nano freeze dry process of preparation of highly bioactive agent and its method of use |
| EP3250184B1 (en) | 2015-01-27 | 2024-12-18 | The Johns Hopkins University | Hypotonic hydrogel formulations for enhanced transport of active agents at mucosal surfaces |
| TWI798161B (zh) | 2015-09-21 | 2023-04-11 | 瑞士商梯瓦製藥國際有限公司 | 持續釋放的奧氮平調配物 |
| CN108347916B (zh) | 2015-10-14 | 2022-02-08 | 先时迈纳米生物科技股份有限公司 | 一种减少冰晶形成的组合物及其方法 |
| WO2017107906A1 (zh) * | 2015-12-22 | 2017-06-29 | 四川科伦药物研究院有限公司 | 一种艾塞那肽微球制剂及其制备方法 |
| MX2019004476A (es) * | 2016-10-20 | 2019-09-23 | Peptron Inc | Metodos para administrar un polipeptido neuroprotector al sistema nervioso central. |
| CA3057438A1 (en) | 2017-03-20 | 2018-09-27 | Teva Pharmaceuticals International Gmbh | Sustained release olanzapine formulaitons |
| JP7054954B2 (ja) * | 2018-01-10 | 2022-04-15 | ジー２ジーバイオ インコーポレイテッド | コラーゲンペプチドを含有したポリカプロラクトン微粒球フィラーおよびその製造方法 |
| US12274787B2 (en) | 2018-12-17 | 2025-04-15 | G2Gbio, Inc. | Sustained-release injection comprising deslorelin, and preparation method therefor |
| US12496279B2 (en) | 2019-04-11 | 2025-12-16 | The Johns Hopkins University | Nanoparticles for drug delivery to brain |
| CA3148426A1 (en) | 2019-07-29 | 2021-02-04 | Peptron, Inc. | Pharmaceutical composition for treating levodopa-induced dyskinesia or for suppressing progression thereof |
| EP4005587A4 (en) * | 2019-07-29 | 2023-08-09 | Peptron, Inc. | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF LEVODOPA-INDUCED DYSKINESIA OR SUPPRESSION OF THEIR PROGRESSION |
| EP4277661A1 (en) | 2021-01-18 | 2023-11-22 | Anton Frenkel | Pharmaceutical dosage form |
| CN117098529A (zh) * | 2021-01-29 | 2023-11-21 | 天温轮特拉皮踢诗 | 初期突发释放受控的贮库组合物及其方法 |
| EP4366726A1 (en) | 2021-07-06 | 2024-05-15 | Mark Hasleton | Treatment of serotonin reuptake inhibitor withdrawal syndrome |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4389330A (en) * | 1980-10-06 | 1983-06-21 | Stolle Research And Development Corporation | Microencapsulation process |
| US5271961A (en) * | 1989-11-06 | 1993-12-21 | Alkermes Controlled Therapeutics, Inc. | Method for producing protein microspheres |
| GB9210574D0 (en) | 1992-05-18 | 1992-07-01 | Ca Nat Research Council | Biotherapeutic cell-coated microspheres for wound/burn and prothesis implant applications |
| JPH09315975A (ja) * | 1995-09-28 | 1997-12-09 | Takeda Chem Ind Ltd | ２−ピペラジノン−１−酢酸誘導体の徐放剤 |
| JP4900984B2 (ja) * | 1997-07-15 | 2012-03-21 | 武田薬品工業株式会社 | 徐放性製剤の製造法 |
| DK1140145T4 (da) * | 1999-01-14 | 2019-07-22 | Amylin Pharmaceuticals Llc | Hidtil ukendte exendinagonistformuleringer og fremgangsmåder til indgivelse deraf |
| PT1143989E (pt) | 1999-01-14 | 2007-03-30 | Amylin Pharmaceuticals Inc | Exendinas para supressão de glucagon |
| DK1246638T4 (da) | 2000-01-10 | 2014-09-22 | Amylin Pharmaceuticals Llc | Anvendelse af extendiner og agonister deraf til behandlingen af hypertriglyceridæmi |
| JP5160005B2 (ja) * | 2000-12-28 | 2013-03-13 | 武田薬品工業株式会社 | 徐放性製剤 |
| KR100566573B1 (ko) | 2002-04-13 | 2006-03-31 | 주식회사 펩트론 | Ｌｈｒｈ 동족체를 함유하는 서방성 미립구의 제조방법 |
| AU2003277446A1 (en) * | 2002-10-17 | 2004-05-04 | Alkermes Controlled Therapeutics, Inc. Ii | Microencapsulation and sustained release of biologically active polypeptides |
| SI21402A (sl) * | 2003-02-12 | 2004-08-31 | LEK farmacevtska dru�ba d.d. | Obloženi delci in farmacevtske oblike |
| ES2375802T3 (es) * | 2004-04-15 | 2012-03-06 | Alkermes Pharma Ireland Limited | Dispositivo de liberación sostenida a base de pol�?mero. |
| US7456254B2 (en) * | 2004-04-15 | 2008-11-25 | Alkermes, Inc. | Polymer-based sustained release device |
| SI1786400T1 (sl) * | 2004-08-12 | 2009-08-31 | Quest Pharmaceutical Services | Farmacevtski sestavki za dajanje biološko aktivnih spojin z nadzorovanim sproščanjem |
| WO2006053175A2 (en) * | 2004-11-10 | 2006-05-18 | Qlt Usa Inc. | A stabilized polymeric delivery system |
-
2007
- 2007-03-27 KR KR1020070029586A patent/KR100805208B1/ko active Active
-
2008
- 2008-01-22 PL PL08712168T patent/PL2134329T3/pl unknown
- 2008-01-22 CA CA2682499A patent/CA2682499C/en active Active
- 2008-01-22 ES ES08712168.7T patent/ES2528282T3/es active Active
- 2008-01-22 WO PCT/KR2008/000397 patent/WO2008117927A1/en not_active Ceased
- 2008-01-22 MX MX2009010280A patent/MX2009010280A/es active IP Right Grant
- 2008-01-22 US US12/532,311 patent/US9155702B2/en active Active
- 2008-01-22 EP EP08712168.7A patent/EP2134329B1/en active Active
- 2008-01-22 BR BRPI0809326A patent/BRPI0809326B8/pt active IP Right Grant
- 2008-01-22 RU RU2009136655/15A patent/RU2463040C2/ru active
- 2008-01-22 CN CN200880009933XA patent/CN101646424B/zh active Active
- 2008-01-22 MY MYPI20093763A patent/MY150087A/en unknown
- 2008-01-22 JP JP2010500816A patent/JP5135428B2/ja active Active
- 2008-01-22 AU AU2008230297A patent/AU2008230297B2/en active Active
-
2009
- 2009-09-14 ZA ZA2009/06381A patent/ZA200906381B/en unknown
- 2009-09-17 IL IL201024A patent/IL201024A/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| IL201024A (en) | 2014-01-30 |
| CN101646424B (zh) | 2013-03-20 |
| BRPI0809326B1 (pt) | 2020-10-13 |
| PL2134329T3 (pl) | 2015-07-31 |
| ES2528282T3 (es) | 2015-02-06 |
| RU2009136655A (ru) | 2011-05-10 |
| ZA200906381B (en) | 2010-11-24 |
| BRPI0809326B8 (pt) | 2021-05-25 |
| MY150087A (en) | 2013-11-29 |
| IL201024A0 (en) | 2010-05-17 |
| EP2134329B1 (en) | 2015-01-07 |
| JP5135428B2 (ja) | 2013-02-06 |
| JP2010522743A (ja) | 2010-07-08 |
| EP2134329A1 (en) | 2009-12-23 |
| CA2682499A1 (en) | 2008-10-02 |
| KR100805208B1 (ko) | 2008-02-21 |
| AU2008230297B2 (en) | 2010-07-29 |
| BRPI0809326A2 (pt) | 2014-09-23 |
| WO2008117927A1 (en) | 2008-10-02 |
| EP2134329A4 (en) | 2013-07-10 |
| CN101646424A (zh) | 2010-02-10 |
| US20100136126A1 (en) | 2010-06-03 |
| US9155702B2 (en) | 2015-10-13 |
| AU2008230297A1 (en) | 2008-10-02 |
| CA2682499C (en) | 2013-01-08 |
| RU2463040C2 (ru) | 2012-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY150087A (en) | Composition and microsphere for controlled- release of exendin, and method of preparing the same | |
| WO2008006716A3 (en) | Improvements relating to pharmaceutical compositions | |
| WO2010056065A3 (en) | Method for preparing microspheres and microspheres produced thereby | |
| TW200640502A (en) | Tablets with improved drug substance dispersibility | |
| WO2010053306A3 (ko) | 메칠페니데이트의 방출 제어용 약제학적 조성물 | |
| WO2009050289A3 (en) | Solid dispersion product containing n-aryl urea-based compound | |
| WO2011077451A3 (en) | Controlled release pharmaceutical composition | |
| NO20081481L (no) | Farmasoytisk sammensetning inneholdende carvedilol, med regulert frigivning | |
| CL2012002909A1 (es) | Procedimiento de preparación de una composición farmacéutica que comprenden a) un centro granulado constituido por granos de principio activo aglomerados en presencia de aglomerante y b) una capa de recubrimiento de dicho centro granulado constituido por matriz grasa; composición farmacéutica; y su uso para administración oral | |
| WO2010017215A3 (en) | Biodegradable microspheres and methods of use thereof | |
| CA2745784A1 (en) | Method of making sustained release microparticles | |
| WO2007143028A3 (en) | Low dielectric constant materials prepared from soluble fullerene clusters | |
| WO2005110369A3 (en) | Sustained-release microspheres and methods of making and using same | |
| WO2010020799A3 (en) | Compositions for the treatment of neoplastic diseases | |
| ATE521339T1 (de) | Pharmazeutische zusammensetzung aus venlafaxin- hydrochlorid mit kontrollierter freisetzung und herstellungsverfahren dafür | |
| WO2010079052A3 (en) | Nanoparticle compositions | |
| WO2006125501A3 (en) | A coating composition | |
| WO2008041073A8 (en) | Sustained release pharmaceutical compositions of venlafaxine and process for preparation thereof | |
| GB2474001A (en) | Pharmaceutical compositions of somatotrophic hormones | |
| WO2014047477A3 (en) | Multilayer biodegradable microparticles for sustained release of therapeutic agents | |
| NO20071139L (no) | Farmasoytisk preparat med langvarig frigivelse omfattende venlafaxin | |
| CL2007003655A1 (es) | Metodo para preparar un producto a base de madera que comprende la aplicacion de una composicion adhesiva que contiene almidon no gelatinizado, y donde la composicion comprende ademas uno o mas polimeros que contienen un grupo amina y un grupo amida | |
| WO2007138557A3 (en) | Controlled-release multiple unit pharmaceutical compositions | |
| TH84442A (th) | ผลิตภัณฑ์ไมโครแคปซูลชนิดปลดปล่อยเร็ว | |
| WO2008102192A3 (en) | Controlled release pharmaceutical compositions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |